Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biofrontera (BFRI) Change in Account Payables (2024 - 2025)

Biofrontera has reported Change in Account Payables over the past 2 years, most recently at $3.4 million for Q4 2025.

For Q4 2025, Change in Account Payables rose 2062.57% year-over-year to $3.4 million; the TTM value through Dec 2025 reached -$2000.0, up 99.86%, while the annual FY2025 figure was -$2000.0, 99.86% up from the prior year.
Change in Account Payables for Q4 2025 was $3.4 million at Biofrontera, up from $1.3 million in the prior quarter.
Over five years, Change in Account Payables peaked at $3.4 million in Q4 2025 and troughed at -$6.1 million in Q2 2025.